Physician profile
Erin M Risco
NPI 1295172989
$10,593.70
in general payments reported to CMS, 2019-2025
29 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,355 · 2022: $1,985 · 2023: $2,720 · 2024: $2,784 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,056 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,056.10 |
| Education | $198.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,402.55 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,496.24 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,126.69 | 2021-2025 | Ilumya, Blu-U, Winlevi |
| Dermavant Sciences, INC. | $779.49 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $677.91 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $586.46 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $521.65 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $482.11 | 2021-2025 | |
| Lilly USA, LLC | $419.23 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $285.48 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $280.64 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $260.19 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $240.38 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $166.92 | 2021-2025 | Anzupgo, Adbry |
| Amgen INC. | $166.48 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $153.40 | 2025 | Vtama |
| Genzyme Corporation | $126.67 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $77.43 | 2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.63 | 2022-2025 | Spevigo |
| Galderma Laboratories, L.P. | $57.37 | 2021-2025 | Nemluvio, Aklief |
| Ani Pharmaceuticals, INC. | $37.11 | 2023 | Apexicon E |
| Almirall LLC | $32.88 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.32 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $29.15 | 2023 | Idacio |
| Janssen Scientific Affairs, LLC | $27.50 | 2022 | |
| Kerecis Limited | $19.16 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biofrontera INC. | $16.42 | 2025 | |
| Botanix Sb INC | $15.90 | 2025 | Sofdra |
| Epi Health, LLC | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Risco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.